Black Diamond Therapeutics, Inc. Common Stock (BDTX) Stock
NASDAQ · BDTX
1.82
Fundamentals
Market cap
$108.01M
Price / Earnings ratio
-2.6x
Price / Sales ratio
2.2x
Price / Book ratio
1.1x
Return on assets
-29.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
NeutralBDTXSeptember 4, 2026
Zacks Investment ResearchNeutral
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
BDTX

Zacks Investment Research
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
NeutralBDTXMay 27, 2026
Zacks Investment ResearchNeutral
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
BDTX

Zacks Investment Research
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
NeutralBDTXMay 27, 2026
Zacks Investment ResearchNeutral
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX

Zacks Investment Research
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
NeutralBDTXMay 27, 2026
Zacks Investment ResearchNeutral
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
BDTX
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
84M55M28M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
172M113M57M0
Revenue to Profit
2025$70.0M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$22.4M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
NeutralBDTXSeptember 4, 2026
Zacks Investment ResearchNeutral
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
BDTX

Zacks Investment Research
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
NeutralBDTXMay 27, 2026
Zacks Investment ResearchNeutral
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
BDTX

Zacks Investment Research
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
NeutralBDTXMay 27, 2026
Zacks Investment ResearchNeutral
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX

Zacks Investment Research
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
NeutralBDTXMay 27, 2026
Zacks Investment ResearchNeutral
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
BDTX

Zacks Investment Research
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
NeutralBDTXMay 25, 2026
Zacks Investment ResearchNeutral
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
BDTX

MarketBeat
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
NeutralBDTXMay 21, 2026
MarketBeatNeutral
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
BDTX

Zacks Investment Research
BDTX Shares Gain 11% in a Week: Here's What You Should Know
NeutralBDTXMay 11, 2026
Zacks Investment ResearchNeutral
BDTX Shares Gain 11% in a Week: Here's What You Should Know
BDTX

Zacks Investment Research
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
NeutralBDTXApril 28, 2026
Zacks Investment ResearchNeutral
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
BDTX

Zacks Investment Research
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
NeutralBDTXApril 23, 2026
Zacks Investment ResearchNeutral
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
BDTX

Zacks Investment Research
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
NeutralBDTXApril 23, 2026
Zacks Investment ResearchNeutral
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
BDTX
About Black Diamond Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees21
CEODr. Mark A. Velleca M.D., Ph.D.
IPO DateJan 30, 2020
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mark A. Velleca M.D., Ph.D. | CEO, President & Chairman | 1964 |
| Mr. Brent Hatzis-Schoch Esq., J.D. | COO & General Counsel | 1965 |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer | 1969 |
| Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer | 1975 |
| Ms. Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller | 1985 |
| Ms. Melanie Morrison | Chief Development Officer | 1975 |
Fundamentals
Valuation
Market cap$108.01M
Price-to-sales ratio2.23
Price-to-book value1.13
Price-earnings ratio-2.60
Return on Equity-36.00%
Return on SalesN/A
Return on Assets-29.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.75
Income Statement
Average volume578,846
EBITDA$-42.95M
1 year high (52w)$4.94
1 year low (52w)$1.60
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.6 | -9.7 | -24.4 | -9.5 | ||||||||
| 2022 | -25.7 | -27.6 | -8.9 | -11.6 | -28.4 | +45.6 | +33.6 | -7.3 | -46.0 | +35.9 | -10.2 | -12.6 |
| 2023 | +63.0 | -40.8 | +0.0 | -25.9 | +17.0 | +134.9 | -20.5 | -8.9 | -19.4 | -32.4 | +26.5 | +19.1 |
| 2024 | +32.0 | +20.9 | +6.1 | +13.0 | -19.0 | -1.5 | +29.6 | +0.7 | -24.6 | -34.3 | -8.3 | -17.4 |
| 2025 | +22.4 | -18.0 | -18.8 | +14.1 | +29.4 | +4.6 | +7.3 | +6.2 | +35.4 | +4.0 | -3.3 | -35.5 |
| 2026 | +0.0 | -2.8 | -12.3 | +13.7 | -14.6 | -18.1 | -8.2 | +20.7 | -7.8 |



